Metabolic syndrome does not affect sustained virologic response of direct-acting antivirals while hepatitis C clearance improves hemoglobin A1c

Table 6 Odds ratio for a decrease of hemoglobin A1c > 0.5 among type 2 diabetes mellitus patients treated with direct acting antiviral

Predictor	Unadjusted OR (95%CI)	Adjusted OR (95%CI)
Age	1.03 (0.95-1.11)	1.07 (0.96-1.20)
Race/ethnicity
White1	1.58 (0.64-3.91)
African American	0.89 (0.32-2.43)	0.52 (0.13-2.06)
Hispanic	0.53 (0.18-1.57)	0.65 (0.16-2.66)
Asian	0.50 (0.02-8.85)	0.8 (0.04-10.01)
Other	0.83 (0.16-4.21)	0.98 (0.12-7.90)
Cirrhosis (by chart review)	0.62 (0.28-1.37)	0.59 (0.20-1.69)
Treatment naïve	0.84 (0.87-4.59)	2.61 (0.92-7.29)
HCV genotype
1a1	0.77 (0.35-1.71)
1b	1.33 (0.49-3.60)	0.79 (0.22-2.86)
2	1.50 (0.41-5.42)	6.75 (0.26-176.51)
3	0.66 (0.15-2.92)	3.81 (0.29-50.00)
Treatment regimen
Sofosbuvir/Simeprevir1	1.23 (0.55-2.75)
Sofosbuvir/Ribavirin	0.75 (0.27-2.09)	0.07 (0.003-1.50)
PrOD	1.60 (0.56-4.56)	0.71 (0.17-2.86)
Ledipasvir/Sofosbuvir	0.66 (0.27-1.62)	0.35 (0.09-1.36)
Overweight	1.36 (0.42-4.35)	0.89 (0.20-1.69)
Obese	1.55 (0.44-5.40)	1.10 (0.20-5.93)
Severely obese	1.08 (0.24-4.94)	0.41 (0.05-3.07)
Very severely obese	0.26 (0.21-3.06)	0.08 (0.003-2.07)
HTN	1.36 (0.38-4.80)	1.15 (0.15-8.86)
HLD	1.69 (0.69-4.09)	1.45 (0.29-7.26)
Metabolic syndrome	1.58 (0.60-4.15)	0.96 (0.10-9.19)
SVR12a	10.67 (1.76-64.7)	7.24 (1.22-42.94)

¹Reference group;

^aP < 0.05. HCV: Hepatitis C virus; HIV: Human immunodeficiency virus; HTN: Hypertension; HLD: Hyperlipidemia; SVR12: Sustained virologic response 12 wk post-treatment; PrOD: Ombitasvir/Paritaprevir/Ritonavir/ Dasabuvir.